Lonza grants UCB Licence to GS Gene Expression System

Published: 7-Mar-2007
Sustainability

Swiss-based life sciences company Lonza Group has granted UCB, of Belgium, a non-exclusive, worldwide license to its GS Gene Expression System (GS: glutamine synthetase).


Swiss-based life sciences company Lonza Group has granted UCB, of Belgium, a non-exclusive, worldwide license to its GS Gene Expression System (GS: glutamine synthetase).

The Research Evaluation Agreement covers the use of the GS Gene Expression System for research and development purposes.

An option to obtain a license to use the GS Gene Expression System for commercial purposes is included in the agreement. Standard payments and licence fees are within the contract, the financial terms of which have not been disclosed.

The GS Gene Expression System, which is owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies. It has been used successfully by more than 80 biotechnology and pharmaceutical companies and around 70 academic laboratories worldwide.

The system is characterised by its speed and ease of use. In addition, these higher-yielding cell lines provide cost-efficient production of therapeutic proteins.

'As a leader in their field, we believe that having UCB select the GS Gene Expression System underscores the importance of this technology for the efficient production of therapeutic antibodies and recombinant proteins,' said Karen Fallen, commercial licensing manager at Lonza.

  • Companies:
  • Lonza
See more

You may also like

Sustainability

Greener horizons: Lonza CHI’s journey towards sustainable capsule production

Read more
From sustainable sourcing to working with drug developers and suppliers to ensure that ingredients and raw materials are processed in an environmentally conscious way, pharmaceutical contract service suppliers are under increasing pressure to implement planet-friendly practices and minimise their emissions

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
  3. Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
  4. Five API manufacturing trends you need to know in 2025 How technology, sustainability and innovation are redefining pharmaceutical production
  5. GEA raises guidance following strong H1 performance Revised forecast reflects improved margins, robust order intake and efficiency gains

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Sustainability

Greener horizons: Lonza CHI’s journey towards sustainable capsule production

From sustainable sourcing to working with drug developers and suppliers to ensure that ingredients and raw materials are processed in an environmentally conscious way, pharmaceutical contract service suppliers are under increasing pressure to implement planet-friendly practices and minimise their emissions
Sustainability

Lonza Capsules & Health Ingredients establishes Center of Applied Sustainability

As part of Lonza Capsules & Health Ingredients’ (CHI) continued focus on sustainability, a new Center of Applied Sustainability has been established to accelerate sustainability efforts: the team will work alongside partners, suppliers and customers to achieve collective environmental goals, with the aim of decreasing the environmental footprint of CHI’s products and operations
Sustainability

Paperless automated monitoring

When looking to expand its drug manufacturing operation in New Jersey, ImClone Systems Inc recognised that eliminating paper-based record keeping was the key to improving the efficiency of its environmental monitoring and QC programme
Manufacturing

A world of difference

Most companies now boast a sustainability strategy. Hilary Ayshford summarises some of the latest thinking in the pharmaceutical manufacturing sector
Sustainability

Lonza and LFB sign antibody-manufacturing agreement

<p>Swiss pharmaceutical firm Lonza and LFB of France are to collaborate on the manufacture of a monoclonal anti-RhD antibody developed by LFB. Under this agreement, the process developed by LFB will be transferred to Lonza, which will provide GMP manufacturing services for supporting the phase III clinical programme.</p>
Sustainability

Elusys Therapeutics and Lonza sign manufacturing agreement

<p>US-based Elusys Therapeutics and Lonza Sales in Switzerland have signed a production contract for Anthim, a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection. </p>
Ingredients

Lonza and Kyowa Hakko extend strategic collaboration

<p>Lonza, of Switzerland, is to license its GS Gene Expression System (GS: glutamine synthetase) to Tokyo-based pharma and biotech company Kyowa Hakko and its US subsidiary BioWa Inc. </p>
Subscribe now